Profile data is unavailable for this security.
About the company
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
- Revenue in CNY (TTM)748.53m
- Net income in CNY-720.11m
- Incorporated2009
- Employees1.49k
- LocationCanSino Biologics IncWest District Biomedical Park, No. 185South Avenue, West District, EconomicTIANJIN 300457ChinaCHN
- Phone+86 2 258213766
- Fax+86 2 258213626
- Websitehttp://www.cansinotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chongqing Genrix Biophrmctcl Co Ltd | 13.56m | -779.42m | 9.98bn | 547.00 | -- | 4.24 | -- | 736.05 | -2.13 | -2.13 | 0.037 | 6.42 | 0.0039 | 0.1009 | 1.37 | 24,790.27 | -22.22 | -- | -23.06 | -- | 55.87 | -- | -5,747.82 | -- | 18.62 | -- | 0.2454 | -- | 154.92 | -- | -39.03 | -- | -- | -- |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.55bn | -34.96m | 10.13bn | 8.06k | -- | 1.23 | -- | 1.06 | -0.0412 | -0.0412 | 8.20 | 6.83 | 0.555 | 3.23 | 4.28 | 1,184,162.00 | -0.3467 | 1.95 | -0.5663 | 3.77 | 39.08 | 40.58 | -0.6248 | 3.43 | 0.6491 | -- | 0.3696 | 26.07 | -13.82 | 0.3618 | -119.05 | -- | -31.58 | -- |
| Changchun BCHT Biotechnology Co | 1.61bn | 414.29m | 10.71bn | 1.24k | 25.87 | 2.55 | -- | 6.66 | 1.00 | 1.00 | 3.88 | 10.15 | 0.3181 | 1.00 | 1.06 | 1,295,333.00 | 8.20 | 9.95 | 10.23 | 12.81 | 87.55 | 86.63 | 25.77 | 24.03 | 1.85 | -- | 0.0147 | 10.55 | 70.30 | 12.36 | 175.98 | 31.37 | 21.04 | -- |
| Cansino Biologics Inc | 748.53m | -720.11m | 10.72bn | 1.49k | -- | 3.12 | -- | 14.33 | -2.92 | -2.92 | 3.03 | 20.46 | 0.0851 | 0.6341 | 1.12 | 501,023.80 | -8.41 | -4.27 | -11.09 | -5.59 | 67.71 | 41.73 | -98.82 | -27.60 | 2.27 | -8.75 | 0.2934 | -- | -65.49 | 163.48 | -63.04 | -- | 30.60 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.48bn | 482.37m | 10.82bn | 2.88k | 22.42 | 2.70 | -- | 3.11 | 1.12 | 1.12 | 8.08 | 9.28 | 0.6872 | 6.42 | 8.53 | 1,208,299.00 | 9.74 | 10.82 | 11.64 | 13.47 | 44.84 | 41.18 | 14.17 | 14.08 | 4.40 | -- | 0.0936 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.58bn | 114.60m | 10.92bn | 2.55k | 97.09 | 1.41 | -- | 4.23 | 0.1194 | 0.1194 | 2.74 | 8.24 | 0.2118 | 1.48 | 0.7645 | 1,014,704.00 | 0.8822 | 3.48 | 1.17 | 4.78 | 34.52 | 38.93 | 4.17 | 10.08 | 2.23 | -- | 0.2888 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
| KPC Pharmaceuticals Inc | 7.55bn | 446.07m | 11.13bn | 5.05k | 24.82 | 2.01 | -- | 1.47 | 0.5924 | 0.5924 | 10.03 | 7.31 | 0.7819 | 2.75 | 2.56 | 1,494,697.00 | 4.64 | 5.42 | 7.75 | 9.13 | 40.84 | 43.68 | 5.94 | 5.70 | 1.51 | -- | 0.172 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
| Liaoning Chengda Biotechnology Co Ltd | 1.72bn | 332.10m | 11.18bn | 1.73k | 33.43 | 1.17 | -- | 6.51 | 0.8032 | 0.8032 | 4.16 | 22.93 | 0.1702 | 0.763 | 1.43 | 991,973.80 | 3.29 | 10.63 | 3.41 | 11.01 | 80.53 | 85.74 | 19.33 | 39.56 | 17.44 | -- | 0.0018 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
Data as of Sep 13 2024. Currency figures normalised to CanSino Biologics Inc's reporting currency: Chinese Yuan Renminbi CNY
1.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 06 Nov 2024 | 335.45k | 0.50% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 222.05k | 0.33% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 203.03k | 0.30% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 118.79k | 0.18% |
| BlackRock Advisors LLCas of 30 Sep 2024 | 101.98k | 0.15% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024 | 90.00k | 0.14% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 75.09k | 0.11% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 47.24k | 0.07% |
| SWS MU Fund Management Co., Ltd.as of 30 Jun 2024 | 47.21k | 0.07% |
| E Fund Management Co., Ltd.as of 30 Sep 2024 | 42.31k | 0.06% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
